- United States
- /
- Life Sciences
- /
- NasdaqGM:QSI
Quantum-Si Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Quantum-Si (NASDAQ:QSI) Third Quarter 2024 Results
Key Financial Results
- Net loss: US$25.3m (loss widened by 2.4% from 3Q 2023).
- US$0.18 loss per share (further deteriorated from US$0.17 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Quantum-Si EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 27%. Earnings per share (EPS) exceeded analyst estimates by 10%.
Looking ahead, revenue is forecast to grow 67% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Life Sciences industry in the US.
Performance of the American Life Sciences industry.
The company's shares are down 12% from a week ago.
Risk Analysis
Before you take the next step you should know about the 4 warning signs for Quantum-Si (1 is a bit unpleasant!) that we have uncovered.
Valuation is complex, but we're here to simplify it.
Discover if Quantum-Si might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGM:QSI
Quantum-Si
A life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS).
Flawless balance sheet slight.